Global Primary Immunodeficiency Therapeutics Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	136 Pages	TechNavio	July, 2024	INF19115235

Best Price Guarantee
Price	from $2,500
Length	136 Pages
Publisher	TechNavio
Published Date	July, 2024
SKU	INF19115235

Global Primary Immunodeficiency Therapeutics Market 2024-2028

Global Primary Immunodeficiency Therapeutics Market 2024-2028

The primary immunodeficiency therapeutics market is forecasted to grow by USD 1699.5 mn during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the primary immunodeficiency therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of immunodeficiency diseases, rising incidences of immune diseases in children, and technological advancements in gene therapy.

Technavio's primary immunodeficiency therapeutics market is segmented as below:

By Disease Type
Antibody deficiency
Cellular immunodeficiency
Innate immune disorders
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing r and d activities as one of the prime reasons driving the primary immunodeficiency therapeutics market growth during the next few years. Also, advancements in genetic technology and rise in government awareness programs about immunodeficiency diseases will lead to sizable demand in the market.

The report on the primary immunodeficiency therapeutics market covers the following areas:

Primary immunodeficiency therapeutics market sizing
Primary immunodeficiency therapeutics market forecast
Primary immunodeficiency therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary immunodeficiency therapeutics market vendors that include ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd.. Also, the primary immunodeficiency therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Disease Type; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Primary Immunodeficiency Therapeutics Market 2018 - 2022; Historic Market Size - Data Table on Global Primary Immunodeficiency Therapeutics Market 2018 - 2022 ($ million); 4.2 Disease Type segment analysis 2018 - 2022; Historic Market Size - Disease Type Segment 2018 - 2022 ($ million); 4.3 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.4 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Disease Type: 6.1 Market segments; Chart on Disease Type - Market share 2023-2028 (%); Data Table on Disease Type - Market share 2023-2028 (%); 6.2 Comparison by Disease Type; Chart on Comparison by Disease Type; Data Table on Comparison by Disease Type; 6.3 Antibody deficiency - Market size and forecast 2023-2028; Chart on Antibody deficiency - Market size and forecast 2023-2028 ($ million); Data Table on Antibody deficiency - Market size and forecast 2023-2028 ($ million); Chart on Antibody deficiency - Year-over-year growth 2023-2028 (%); Data Table on Antibody deficiency - Year-over-year growth 2023-2028 (%); 6.4 Cellular immunodeficiency - Market size and forecast 2023-2028; Chart on Cellular immunodeficiency - Market size and forecast 2023-2028 ($ million); Data Table on Cellular immunodeficiency - Market size and forecast 2023-2028 ($ million); Chart on Cellular immunodeficiency - Year-over-year growth 2023-2028 (%); Data Table on Cellular immunodeficiency - Year-over-year growth 2023-2028 (%); 6.5 Innate immune disorders - Market size and forecast 2023-2028; Chart on Innate immune disorders - Market size and forecast 2023-2028 ($ million); Data Table on Innate immune disorders - Market size and forecast 2023-2028 ($ million); Chart on Innate immune disorders - Year-over-year growth 2023-2028 (%); Data Table on Innate immune disorders - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by Disease Type; Market opportunity by Disease Type ($ million); Data Table on Market opportunity by Disease Type ($ million)
7 Customer Landscape: 7.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
8 Geographic Landscape: 8.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2023-2028 (%); Data Table on Market share By Geographical Landscape 2023-2028 (%); 8.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 8.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 8.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 8.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 8.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 8.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 8.8 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 8.9 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 8.10 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 8.11 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 8.12 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
9 Drivers, Challenges, and Opportunity/Restraints: 9.1 Market drivers; 9.2 Market challenges; 9.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 9.4 Market opportunities/restraints
10 Competitive Landscape: 10.1 Overview; 10.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 10.3 Landscape disruption; Overview on factors of disruption; 10.4 Industry risks; Impact of key risks on business
11 Competitive Analysis: 11.1 Companies profiled; Companies covered; 11.2 Market positioning of companies; Matrix on companies position and classification; 11.3 Bayer AG; Bayer AG - Overview; Bayer AG - Business segments; Bayer AG - Key news; Bayer AG - Key offerings; Bayer AG - Segment focus; 11.4 Bio Products Laboratory Ltd.; Bio Products Laboratory Ltd. - Overview; Bio Products Laboratory Ltd. - Product / Service; Bio Products Laboratory Ltd. - Key offerings; 11.5 Biocon Ltd.; Biocon Ltd. - Overview; Biocon Ltd. - Business segments; Biocon Ltd. - Key offerings; Biocon Ltd. - Segment focus; 11.6 Biotest AG; Biotest AG - Overview; Biotest AG - Business segments; Biotest AG - Key offerings; Biotest AG - Segment focus; 11.7 CSL Ltd.; CSL Ltd. - Overview; CSL Ltd. - Business segments; CSL Ltd. - Key news; CSL Ltd. - Key offerings; CSL Ltd. - Segment focus; 11.8 Grifols SA; Grifols SA - Overview; Grifols SA - Business segments; Grifols SA - Key news; Grifols SA - Key offerings; Grifols SA - Segment focus; 11.9 Kedrion Spa; Kedrion Spa - Overview; Kedrion Spa - Product / Service; Kedrion Spa - Key offerings; 11.10 Octapharma AG; Octapharma AG - Overview; Octapharma AG - Product / Service; Octapharma AG - Key offerings; 11.11 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; 11.12 Takeda Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Co. Ltd. - Overview; Takeda Pharmaceutical Co. Ltd. - Product / Service; Takeda Pharmaceutical Co. Ltd. - Key news; Takeda Pharmaceutical Co. Ltd. - Key offerings
12 Appendix: 12.1 Scope of the report; 12.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 12.3 Currency conversion rates for US$; Currency conversion rates for US$; 12.4 Research methodology; Research methodology; 12.5 Data procurement; Information sources; 12.6 Data validation; Data validation; 12.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 12.8 Data synthesis; Data synthesis; 12.9 360 degree market analysis; 360 degree market analysis; 12.10 List of abbreviations; List of abbreviations; Exhibits:; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Disease Type; Exhibits6: Executive Summary - Chart on Incremental Growth; Exhibits7: Executive Summary - Data Table on Incremental Growth; Exhibits8: Executive Summary - Chart on Company Market Positioning; Exhibits9: Parent Market; Exhibits10: Data Table on - Parent Market; Exhibits11: Market characteristics analysis; Exhibits12: Value Chain Analysis; Exhibits13: Offerings of companies included in the market definition; Exhibits14: Market segments; Exhibits15: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits16: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Historic Market Size - Data Table on Global Primary Immunodeficiency Therapeutics Market 2018 - 2022 ($ million); Exhibits20: Historic Market Size - Disease Type Segment 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on Disease Type - Market share 2023-2028 (%); Exhibits31: Data Table on Disease Type - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by Disease Type; Exhibits33: Data Table on Comparison by Disease Type; Exhibits34: Chart on Antibody deficiency - Market size and forecast 2023-2028 ($ million); Exhibits35: Data Table on Antibody deficiency - Market size and forecast 2023-2028 ($ million); Exhibits36: Chart on Antibody deficiency - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Antibody deficiency - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Cellular immunodeficiency - Market size and forecast 2023-2028 ($ million); Exhibits39: Data Table on Cellular immunodeficiency - Market size and forecast 2023-2028 ($ million); Exhibits40: Chart on Cellular immunodeficiency - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Cellular immunodeficiency - Year-over-year growth 2023-2028 (%); Exhibits42: Chart on Innate immune disorders - Market size and forecast 2023-2028 ($ million); Exhibits43: Data Table on Innate immune disorders - Market size and forecast 2023-2028 ($ million); Exhibits44: Chart on Innate immune disorders - Year-over-year growth 2023-2028 (%); Exhibits45: Data Table on Innate immune disorders - Year-over-year growth 2023-2028 (%); Exhibits46: Market opportunity by Disease Type ($ million); Exhibits47: Data Table on Market opportunity by Disease Type ($ million); Exhibits48: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits49: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits50: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits51: Chart on Geographic comparison; Exhibits52: Data Table on Geographic comparison; Exhibits53: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits54: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits55: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits56: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits57: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits58: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits59: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits60: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits61: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits62: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits63: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits64: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits65: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits66: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits67: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits68: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits69: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits70: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits71: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits72: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits73: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits89: Market opportunity By Geographical Landscape ($ million); Exhibits90: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits91: Impact of drivers and challenges in 2023 and 2028; Exhibits92: Overview on criticality of inputs and factors of differentiation; Exhibits93: Overview on factors of disruption; Exhibits94: Impact of key risks on business; Exhibits95: Companies covered; Exhibits96: Matrix on companies position and classification; Exhibits97: Bayer AG - Overview; Exhibits98: Bayer AG - Business segments; Exhibits99: Bayer AG - Key news; Exhibits100: Bayer AG - Key offerings; Exhibits101: Bayer AG - Segment focus; Exhibits102: Bio Products Laboratory Ltd. - Overview; Exhibits103: Bio Products Laboratory Ltd. - Product / Service; Exhibits104: Bio Products Laboratory Ltd. - Key offerings; Exhibits105: Biocon Ltd. - Overview; Exhibits106: Biocon Ltd. - Business segments; Exhibits107: Biocon Ltd. - Key offerings; Exhibits108: Biocon Ltd. - Segment focus; Exhibits109: Biotest AG - Overview; Exhibits110: Biotest AG - Business segments; Exhibits111: Biotest AG - Key offerings; Exhibits112: Biotest AG - Segment focus; Exhibits113: CSL Ltd. - Overview; Exhibits114: CSL Ltd. - Business segments; Exhibits115: CSL Ltd. - Key news; Exhibits116: CSL Ltd. - Key offerings; Exhibits117: CSL Ltd. - Segment focus; Exhibits118: Grifols SA - Overview; Exhibits119: Grifols SA - Business segments; Exhibits120: Grifols SA - Key news; Exhibits121: Grifols SA - Key offerings; Exhibits122: Grifols SA - Segment focus; Exhibits123: Kedrion Spa - Overview; Exhibits124: Kedrion Spa - Product / Service; Exhibits125: Kedrion Spa - Key offerings; Exhibits126: Octapharma AG - Overview; Exhibits127: Octapharma AG - Product / Service; Exhibits128: Octapharma AG - Key offerings; Exhibits129: Pfizer Inc. - Overview; Exhibits130: Pfizer Inc. - Product / Service; Exhibits131: Pfizer Inc. - Key news; Exhibits132: Pfizer Inc. - Key offerings; Exhibits133: Takeda Pharmaceutical Co. Ltd. - Overview; Exhibits134: Takeda Pharmaceutical Co. Ltd. - Product / Service; Exhibits135: Takeda Pharmaceutical Co. Ltd. - Key news; Exhibits136: Takeda Pharmaceutical Co. Ltd. - Key offerings; Exhibits137: Inclusions checklist; Exhibits138: Exclusions checklist; Exhibits139: Currency conversion rates for US$; Exhibits140: Research methodology; Exhibits141: Information sources; Exhibits142: Data validation; Exhibits143: Validation techniques employed for market sizing; Exhibits144: Data synthesis; Exhibits145: 360 degree market analysis; Exhibits146: List of abbreviations